NCT05947474View on ClinicalTrials.gov

ORB-011 In Patients With Advanced Solid Tumors

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

August 21, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Cancer
Interventions
DRUG

ORB-011

Drug: ORB-011 is dosed via IV infusion

Trial Locations (2)

77030

MD Anderson Center, Houston

85258

Honor Health Research Institute, Scottsdale

Sponsors
All Listed Sponsors
lead

Orionis Biosciences Inc

INDUSTRY

NCT05947474 - ORB-011 In Patients With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter